AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

A federal jury in Delaware found that Revance's rival product infringed patents for Allergan's market-leading neurotoxin ...

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

A federal jury July 18 said Revance Therapeutics' skin medication infringed on patents for anti-wrinkle treatment Botox and owes AbbVie-owned Allergan $56 million.

Evolus is demonstrating strong market share gains, successful new product launches, and reaffirmed 2025 revenue guidance despite recent share price volatility. Read the stock analysis here.

Detailed price information for Dermata Therapeutics Inc WT (DRMAW-Q) from The Globe and Mail including charting and trades.

The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to advance at a resilient ...

Aesthetic medicine market exhibits robust procedural expansion, technology-driven accessibility, and rising preventive demand ...

ExodusPoint burst onto the hedge fund scene in 2018 with the largest launch in history — raising $8.5 billion out of the gate — powered by institutional backing, an elite Wall Street pedigree, and ...